Biogen (NASDAQ:BIIB) Stock Rating Raised to “Strong-Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Biogen (NASDAQ:BIIB – Free Report) from a buy rating to a strong-buy rating in a research note released on Saturday morning,Wall Street Zen reports.

A number of other equities analysts have also commented on the company. Bank of America lifted their price objective on Biogen from $219.00 to $244.00 and gave the stock a “neutral” rating in a research note on Thursday, October 22nd. Barclays increased their target price on shares of Biogen from $200.00 to $230.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 28th. Royal Bank Of Canada raised their price target on shares of Biogen from $256.00 to $272.00 and gave the stock an “outperform” rating in a report on Thursday, October 29th. TD Cowen raised their price target on shares of Biogen from $250.00 to $260.00 and gave the stock a “buy” rating in a report on Thursday, October 29th. Finally, JPMorgan Chase & Co. upgraded shares of Biogen from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $210.00 to $300.00 in a research report on Monday, October 12th. One analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $254.41.

View Our Latest Stock Analysis on Biogen

Biogen Trading Up 1.2%

NASDAQ BIIB traded up $2.92 on Friday, reaching $253.40. The company had a trading volume of 1,028,905 shares, compared to its average volume of 1,250,373. The firm has a market cap of $37.46 billion, a price-to-earnings ratio of 108.29, a P/E/G ratio of 2.84 and a beta of 0.10. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.95 and a quick ratio of 1.37. Biogen has a fifty-two week low of $160.36 and a fifty-two week high of $261.00. The business has a 50 day moving average of $233.35 and a two-hundred day moving average of $205.04.

Biogen (NASDAQ:BIIB – Get Free Report) last announced its earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 EPS for the quarter, topping the consensus estimate of $1.99 by $0.63. Biogen had a return on equity of 9.38% and a net margin of 3.37%. The firm had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.63 billion. During the same period in the previous year, the business earned $4.81 EPS. The business’s quarterly revenue was up 10.6% compared to the same quarter last year. Analysts forecast that Biogen will post 12.46 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of BIIB. State Street Corp raised its holdings in shares of Biogen by 830.1% during the third quarter. State Street Corp now owns 136,622,812 shares of the biotechnology company’s stock valued at $30,860,361,000 after purchasing an additional 121,934,158 shares during the period. BlackRock Inc. bought a new position in shares of Biogen during the 2nd quarter worth about $3,453,878,000. Primecap Management Co. CA acquired a new stake in shares of Biogen in the 2nd quarter valued at about $3,274,304,000. Public Sector Pension Investment Board grew its stake in shares of Biogen by 10,085.8% in the 3rd quarter. Public Sector Pension Investment Board now owns 2,466,095 shares of the biotechnology company’s stock valued at $557,042,000 after buying an additional 2,441,884 shares during the period. Finally, Russell Investments Group Ltd. increased its position in Biogen by 1,524.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 2,175,055 shares of the biotechnology company’s stock valued at $491,301,000 after buying an additional 2,041,161 shares in the last quarter. 87.93% of the stock is owned by institutional investors.

About Biogen

(Get Free Report)

Biogen is a biotechnology company focused on developing and commercializing medicines for neurological and rare diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy and Friedreich’s ataxia. Its products include multiple sclerosis treatments such as Tysabri, Tecfidera and Vumerity, and Skyclarys for Friedreich’s ataxia. Biogen shares rights to several medicines with other companies, including Leqembi for Alzheimer’s disease with Eisai and Spinraza for spinal muscular atrophy with Ionis Pharmaceuticals.

Further Reading

Analyst Recommendations for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.